ArticleAllergy2026
Successful Application of the Mast Cell Activation Test in Immediate Hypersensitivity to Amoxicillin.
Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Under the Drapes: Unmasking the Mechanisms and Clinical Diagnosis of Perioperative Hypersensitivity.Current allergy and asthma reports · 2026Review
- In vitro diagnostics of drug hypersensitivity reactions.Allergologie select · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundImmediate drug allergic reactions (IDAR) to betalactams are frequent, yet mislabelling remains common and negatively impacts clinical decisions. Conventional diagnostics such as STs and drug provocation are effective but limited by time, risk, and contraindications in severe cases. In vitro alternatives-sIgEquantification and basophil activation tests (BAT)-offer safer options, although performance may be affected by biological variability and suboptimal sensitivity with an important drawback for the latter in patients with non-releaser basophils. This study aimed to evaluate a mast cell activation test (MAT) based on human CD34
methodsCD34
resultsMAT with free AX achieved 53.57% sensitivity, G4/G5-AXO reached 46.43%, and all methods maintained 100% specificity. Combining results with AX or dendrimeric stimuli increased sensitivity to 75% while preserving specificity. Importantly, MAT identified positive cases among BAT non-releasers and patients with undetectable sIgE.
conclusionsUnder optimized conditions, MAT using dMCs and different AX determinants reached 75% sensitivity and 100% specificity. The complementary use of free AX and dendrimeric conjugates expands detection across heterogeneous IgE reactivity profiles from AX-allergic patients, reinforcing the diagnostic value of advanced cellular models and engineered allergens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.